BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 1.666
Totale 1.666
Nazione #
IT - Italia 1.666
Totale 1.666
Città #
Genova 1.000
Rapallo 386
Genoa 274
Bordighera 6
Totale 1.666
Nome #
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 125
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 118
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 113
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 103
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 88
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 87
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 81
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 81
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 74
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 73
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 71
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 70
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 66
Vinflunine for the treatment of non-small cell lung cancer 63
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 56
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 56
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 52
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 50
Afatinib for the treatment of non-small cell lung cancer 46
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 45
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 42
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 41
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 40
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 37
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 37
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 29
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 24
Totale 1.768
Categoria #
all - tutte 7.453
article - articoli 7.453
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.906


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201931 0 0 0 0 0 0 0 0 0 0 15 16
2019/2020264 12 13 9 17 22 29 31 27 26 46 30 2
2020/2021448 11 28 23 157 40 21 11 33 42 37 26 19
2021/2022296 16 8 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024240 7 24 11 36 20 66 14 25 11 26 0 0
Totale 1.768